See if Sucraid® is right for your patients diagnosed
with CSID.
Figure 1. Sucrose metabolism by sucrase. Sucrase metabolizes sucrose into its constituent subunits, glucose and fructose, to increase their gastrointestinal absorption.2
This disease has historically been described as an autosomal recessive disorder associated with homozygous or compound heterozygous genotypes of pathogenic SI gene mutations. So far, 37 distinct SI gene mutations have been identified in patients with a confirmed diagnosis of CSID based on enzyme activity from a small bowel biopsy.3-11
The SI gene is very large (more than 100 kilobase pairs), and there are more than 2,000 known, rare mutations, many of which have not been thoroughly investigated.12 Recent research has found that CSID patients have a spectrum of phenotypic expression and severity associated with remnant enzyme activity, total carbohydrate consumption, and a variety of genotypes including SI homozygotes and compound heterozygotes.13
Most importantly, the pathophysiology of CSID is defined by a lack of functional sucrase activity within the small intestine, the enzyme that metabolizes sucrose to its constituent glucose and fructose subunits (Figure 1). While sucrose intolerance is a cardinal feature, CSID can manifest with varying degrees of starch intolerance. Symptom severity is a function of residual sucrase and isomaltase activity, the amount of sugar and starch consumed, the presence of other foods that may have a buffering effect, and the rate of gastric transit.14
Sucrase-isomaltase deficiency has clinically significant consequences, as failure to absorb dietary sucrose and starch may impact the absorption of other nutrients, as well as the hormonal regulation of gastrointestinal function. This is because unabsorbed carbohydrates can accelerate small intestine transit and contribute to malabsorption of starch, fat, and monosaccharides.4 Normal postprandial increases in hormones such as insulin, C-peptide, and gastric inhibitory peptide may be disrupted.14 For these reasons, patients with CSID are at risk for chronic malnutrition. Indeed, failure to thrive or low body mass index are characteristics of the disease.15
Sucrase-isomaltase is an integral glycoprotein heterodimer enzyme involved in carbohydrate metabolism and expressed in the brush border membrane of cells lining the small intestine.14 Sucrase-isomaltase is synthesized, glycosylated, and transported to the apical membrane of the microvilli in the intestinal lumen. In the intestinal brush border, the two enzyme subunits dissociate and the two individual subunits become membrane bound and are associated by noncovalent, strong ionic interactions.14,16-18
Figure 2. Range of presenting symptoms in 23 pediatric patients diagnosed with CSID15
The primary symptom of CSID is mild to severe, chronic, watery diarrhea.14 In addition, fermentation of excess, unabsorbed dietary saccharides by resident intestinal colonic bacteria can result in gassiness, abdominal distention, pain, accelerated motility, and explosive, acidic diarrhea.14 Chronic, watery diarrhea and failure to thrive are the most common symptoms of CSID in infants and toddlers.14,15 Other manifestations include colic, irritability, excoriated buttocks, diaper rash, and vomiting.14,15,19 However, symptoms of CSID do not manifest in infants until they begin to ingest sucrose and starch-containing foods (for example, juices, most common baby foods, medications sweetened with sucrose), because breast milk does not contain sucrose.14 A small number of patients may need to be hospitalized for diarrhea-induced dehydration, malnutrition, muscle wasting, and weakness.19 In some ethnic populations that maintain a traditional protein-rich diet, notably indigenous populations of Greenland, Alaska and Canada, a low-carbohydrate, high-protein, high-fat diet may mask symptoms.14,19
Because it is genetic, CSID is not a disease that a patient can outgrow. Indeed, symptoms persist in adults, but may appear less severe than those experienced by children due to diet and the length of the GI tract. However, in patients with CSID with some residual SI activity, expression of the SI enzyme in the brush border may be induced by hormonal factors, such as corticosteroids and thyroxine, and dietary factors, such as a high-sucrose, high carbohydrate diet.14
As with pediatric patients, the clinical presentation of CSID in adults varies. In some adults, the symptoms may be limited to an increase in bowel movement (BM) frequency, reduced stool consistency (looser stools or watery stools), abdominal distention, and flatulence (gas). Episodic watery diarrhea may also occur after eating a meal that contains high levels of sucrose. In some individuals affected with CSID, diarrhea may alternate with constipation, particularly when taking common antidiarrheal medications, which may lead to a misdiagnosis of another gastrointestinal (GI) condition, such as irritable bowel syndrome-alternating (IBS-A).14
Figure 3. In individuals with normal digestion of sucrose, sucrose is metabolized by sucrase (purple) into two subunits, glucose (gold) and fructose (brown). With CSID, sucrase is absent or dysfunctional, and sucrose cannot be metabolized. Thus, sucrose is not absorbed by the small intestine and undergoes bacterial fermentation in the intestine. The fermentation byproducts are gases, organic acids, or other osmotically-active molecules, causing abdominal distention and pain, and water retention producing watery diarrhea.
IMPORTANT SAFETY INFORMATION:
Sucraid® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older.
